Skip to main content
. 2023 Jan 18;41(Suppl 1):e1107–e1115. doi: 10.1055/a-1990-2633

Fig. 2.

Fig. 2

Rates of RSV-related hospitalizations among palivizumab-treated patients in observational studies and phase III trials. *Reported over a 7-month follow-up period in the United States. †Higher rates observed in extremely premature infants (≤28 WGA). ‡Higher rates observed in BPD patients with a history of premature birth and low birth weight. ¥Higher rate observed in patients with severe BPD. BPD, bronchopulmonary dysplasia; CHD, congenital heart disease; RSV, respiratory syncytial virus; WGA, week gestational age.